STOCK TITAN
  1. Home
  2. News
  3. TFFP

TFF Pharmaceuticals, Inc. - $TFFP STOCK NEWS

Welcome to our dedicated page for TFF Pharmaceuticals news (Ticker: $TFFP), a resource for investors and traders seeking the latest updates and insights on TFF Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TFF Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TFF Pharmaceuticals's position in the market.

News
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) appoints Thomas B. King to its Board of Directors. King brings over 30 years of executive leadership and board experience in the life sciences industry, with a track record of successful stock offerings and M&A transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
management
-
News
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) appoints Michael Patane, Ph.D., a leader in drug discovery and development, to its Board of Directors, bringing two decades of experience to the clinical-stage biopharmaceutical company focused on innovative drug products based on its patented Thin Film Freezing (TFF) technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.43%
Tags
management
-
News
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) appoints Catherine Lee, J.D. to its Board of Directors. With over 25 years of legal and business experience, Ms. Lee brings a wealth of knowledge to the company, having served as General Counsel and Corporate Secretary for multiple companies within the life sciences sector. Her appointment is expected to contribute to TFF Pharmaceuticals' strategic decision-making, product development, and potential partnership opportunities, as the company advances its two clinical programs and its patented Thin Film Freezing (TFF) technology platform gains recognition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.43%
Tags
management
News
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (TFFP) to participate in the 2023 Benchmark Discovery One-on-One Investor Conference in New York City. The company has two products in Phase 2 development and is expecting to release interim data from both studies in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences
-
News
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) reports Q3 2023 financial results and provides corporate update, including progress on TFF VORI and TFF TAC Phase 2 trials. The company remains on track to report initial data by the end of 2023, addressing unmet needs in rare disease indications. Recent highlights include intranasal delivery research, equity financing, and Expanded Access Program for TFF VORI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
earnings
-
News
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the feasibility of intranasal delivery of monoclonal antibodies using their Thin Film Freezing technology. Research showed that the technology can convert mAbs into aerosolizable dry powders for delivery using Aptar Pharma’s Unidose Powder Nasal Spray System. The results indicated that Thin Film Freezing did not cause an increase in high molecular weight species, making it a promising approach for intranasal drug delivery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
News
TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) to Hold Conference Call and Webcast on November 14, 2023 to Discuss Q3 2023 Financial Results and Recent Corporate and Clinical Developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.85%
Tags
earnings
-
News
TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines
Rhea-AI Summary
TFF Pharmaceuticals congratulates Drew Weissman, M.D., Ph.D. for receiving the Nobel Prize in Physiology or Medicine for his work on mRNA COVID-19 vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
management covid-19
-
News
TFF Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
TFF Pharmaceuticals CEO to attend investor meetings at healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences
News
TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023
Rhea-AI Summary
TFF Pharmaceuticals, Inc. CEO to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences
Stock TFFP logo
TFF Pharmaceuticals, Inc.

Nasdaq:TFFP

TFFP Rankings

N/A Ranked by Market Cap
#5435 Ranked by Stock Gains
N/A Ranked by Dividends

TFFP Stock Data

6.85M
2.23M
4.71%
13.87%
3.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About TFFP

tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.